Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1991 Jun;65(6):3400–3405. doi: 10.1128/jvi.65.6.3400-3405.1991

Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection.

D L Lodmell 1, J W Sumner 1, J J Esposito 1, W J Bellini 1, L C Ewalt 1
PMCID: PMC241005  PMID: 2033678

Abstract

Raccoon poxvirus (RCN) recombinants expressing the rabies virus internal structural nucleoprotein (RCN-N) protected A/WySnJ mice against a lethal challenge with street rabies virus (SRV). Maximum survival was achieved following vaccination by tail scratch and footpad (FP) SRV challenge. RCN-N-vaccinated mice inoculated in the FP with SRV were resistant to infection for at least 54 weeks postvaccination. Protection was also elicited by RCN recombinants expressing the rabies virus glycoprotein (RCN-G). Vaccination with RCN-G evoked rabies virus neutralizing antibody. Rabies virus neutralizing antibody was not detected in RCN-N-vaccinated mice prior to or following SRV infection. Radioimmunoprecipitation assays showed that sera from RCN-N-vaccinated mice which survived SRV infection did not contain antibody to SRV structural protein G, M, or NS. The mechanism(s) of N-induced resistance appears to correlate with the failure of peripherally inoculated SRV to enter the central nervous system (CNS). Support for this correlation with resistance was documented by the observations that SRV-inoculated RCN-N-vaccinated mice did not develop clinical signs of CNS rabies virus infection, infectious SRV was not detected in the spinal cord or brain following FP challenge, and all RCN-N-vaccinated mice died following direct intracranial infection of the CNS with SRV. These results suggest that factors other than anti-G neutralizing antibody are important in resistance to rabies virus and that the N protein should be considered for incorporation with the G protein in recombinant vaccines.

Full text

PDF
3400

Images in this article

3403Image
on p.3403

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander A. D., Flyger V., Herman Y. F., McConnell S. J., Rothstein N., Yager R. H. Survey of wild mammals in a Chesapeake Bay area for selected zoonoses. J Wildl Dis. 1972 Apr;8(2):119–126. doi: 10.7589/0090-3558-8.2.119. [DOI] [PubMed] [Google Scholar]
  2. Andrew M. E., Coupar B. E., Boyle D. B., Ada G. L. The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol. 1987 Jan;25(1):21–28. doi: 10.1111/j.1365-3083.1987.tb01042.x. [DOI] [PubMed] [Google Scholar]
  3. Andrew M. E., Coupar B. E. Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand J Immunol. 1988 Jul;28(1):81–85. doi: 10.1111/j.1365-3083.1988.tb02418.x. [DOI] [PubMed] [Google Scholar]
  4. Boere W. A., Benaissa-Trouw B. J., Harmsen T., Erich T., Kraaijeveld C. A., Snippe H. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J Virol. 1985 May;54(2):546–551. doi: 10.1128/jvi.54.2.546-551.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brochier B. M., Languet B., Blancou J., Kieny M. P., Lecocq J. P., Costy F., Desmettre P., Pastoret P. P. Use of recombinant vaccinia-rabies virus for oral vaccination of fox cubs (Vulpes vulpes, L) against rabies. Vet Microbiol. 1988 Oct;18(2):103–108. doi: 10.1016/0378-1135(88)90055-7. [DOI] [PubMed] [Google Scholar]
  6. Brochier B., Thomas I., Bauduin B., Leveau T., Pastoret P. P., Languet B., Chappuis G., Desmettre P., Blancou J., Artois M. Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies. Vaccine. 1990 Apr;8(2):101–104. doi: 10.1016/0264-410x(90)90129-a. [DOI] [PubMed] [Google Scholar]
  7. Bunschoten H., Gore M., Claassen I. J., Uytdehaag F. G., Dietzschold B., Wunner W. H., Osterhaus A. D. Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol. 1989 Feb;70(Pt 2):291–298. doi: 10.1099/0022-1317-70-2-291. [DOI] [PubMed] [Google Scholar]
  8. Celis E., Ou D., Dietzschold B., Koprowski H. Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients. J Virol. 1988 Sep;62(9):3128–3134. doi: 10.1128/jvi.62.9.3128-3134.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chesebro B., Wehrly K., Cloyd M., Britt W., Portis J., Collins J., Nishio J. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology. 1981 Jul 15;112(1):131–144. doi: 10.1016/0042-6822(81)90619-x. [DOI] [PubMed] [Google Scholar]
  10. Cho S., Narahara H., Mifune K., Kawai A. Murine T cell clones directed to rabies virus: isolation and some of their properties. J Gen Virol. 1987 Apr;68(Pt 4):1115–1123. doi: 10.1099/0022-1317-68-4-1115. [DOI] [PubMed] [Google Scholar]
  11. Cox J. H., Dietzschold B., Schneider L. G. Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun. 1977 Jun;16(3):754–759. doi: 10.1128/iai.16.3.754-759.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dietzschold B., Cox J. H., Schneider L. G. Rabies virus strains: a comparison study by polypeptide analysis of vaccine strains with different pathogenic patterns. Virology. 1979 Oct 15;98(1):63–75. doi: 10.1016/0042-6822(79)90525-7. [DOI] [PubMed] [Google Scholar]
  13. Dietzschold B., Wang H. H., Rupprecht C. E., Celis E., Tollis M., Ertl H., Heber-Katz E., Koprowski H. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9165–9169. doi: 10.1073/pnas.84.24.9165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Esposito J. J., Knight J. C., Shaddock J. H., Novembre F. J., Baer G. M. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology. 1988 Jul;165(1):313–316. doi: 10.1016/0042-6822(88)90692-7. [DOI] [PubMed] [Google Scholar]
  15. Esposito J., Brechling K., Baer G., Moss B. Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies. Virus Genes. 1987 Nov;1(1):7–21. doi: 10.1007/BF00125682. [DOI] [PubMed] [Google Scholar]
  16. Grosfeld H., Velan B., Leitner M., Cohen S., Lustig S., Lachmi B. E., Shafferman A. Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. J Virol. 1989 Aug;63(8):3416–3422. doi: 10.1128/jvi.63.8.3416-3422.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kawano H., Mifune K., Ohuchi M., Mannen K., Cho S., Hiramatsu K., Shichijo A. Protection against rabies in mice by a cytotoxic T cell clone recognizing the glycoprotein of rabies virus. J Gen Virol. 1990 Feb;71(Pt 2):281–287. doi: 10.1099/0022-1317-71-2-281. [DOI] [PubMed] [Google Scholar]
  18. Kieny M. P., Lathe R., Drillien R., Spehner D., Skory S., Schmitt D., Wiktor T., Koprowski H., Lecocq J. P. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature. 1984 Nov 8;312(5990):163–166. doi: 10.1038/312163a0. [DOI] [PubMed] [Google Scholar]
  19. Lafon M., Lafage M. Antiviral activity of monoclonal antibodies specific for the internal proteins N and NS of rabies virus. J Gen Virol. 1987 Dec;68(Pt 12):3113–3123. doi: 10.1099/0022-1317-68-12-3113. [DOI] [PubMed] [Google Scholar]
  20. Lafon M., Wiktor T. J., Macfarlan R. I. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol. 1983 Apr;64(Pt 4):843–851. doi: 10.1099/0022-1317-64-4-843. [DOI] [PubMed] [Google Scholar]
  21. Lefrancois L. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J Virol. 1984 Jul;51(1):208–214. doi: 10.1128/jvi.51.1.208-214.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Prevec L., Campbell J. B., Christie B. S., Belbeck L., Graham F. L. A recombinant human adenovirus vaccine against rabies. J Infect Dis. 1990 Jan;161(1):27–30. doi: 10.1093/infdis/161.1.27. [DOI] [PubMed] [Google Scholar]
  23. Pusateri A. M., Ewalt L. C., Lodmell D. L. Nonspecific inhibition of encephalomyocarditis virus replication by a type II interferon released from unstimulated cells of Mycobacterium tuberculosis-sensitized mice. J Immunol. 1980 Mar;124(3):1277–1283. [PubMed] [Google Scholar]
  24. Rhim J. S., Cho H. Y., Huebner R. J. Non-producer human cells induced by murine sarcoma virus. Int J Cancer. 1975 Jan 15;15(1):23–29. doi: 10.1002/ijc.2910150104. [DOI] [PubMed] [Google Scholar]
  25. Schneider L. G., Dietzschold B., Dierks R. E., Matthaeus W., Enzmann P. J., Strohmaier K. Rabies group-specific ribonucleoprotein antigen and a test system for grouping and typing of rhabdoviruses. J Virol. 1973 May;11(5):748–755. doi: 10.1128/jvi.11.5.748-755.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Smith J. S., Yager P. A., Baer G. M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ. 1973 May;48(5):535–541. [PMC free article] [PubMed] [Google Scholar]
  27. Stanley J., Cooper S. J., Griffin D. E. Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J Virol. 1986 Apr;58(1):107–115. doi: 10.1128/jvi.58.1.107-115.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tan C. H., Yap E. H., Singh M., Deubel V., Chan Y. C. Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus. J Gen Virol. 1990 Mar;71(Pt 3):745–749. doi: 10.1099/0022-1317-71-3-745. [DOI] [PubMed] [Google Scholar]
  29. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine. 1988 Dec;6(6):497–503. doi: 10.1016/0264-410x(88)90100-4. [DOI] [PubMed] [Google Scholar]
  30. Thomas E. K., Palmer E. L., Obijeski J. F., Nakano J. H. Further characterization of Raccoonpox virus. Arch Virol. 1975;49(2-3):217–227. doi: 10.1007/BF01317540. [DOI] [PubMed] [Google Scholar]
  31. Thomas I., Brochier B., Languet B., Blancou J., Peharpre D., Kieny M. P., Desmettre P., Chappuis G., Pastoret P. P. Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route. J Gen Virol. 1990 Jan;71(Pt 1):37–42. doi: 10.1099/0022-1317-71-1-37. [DOI] [PubMed] [Google Scholar]
  32. Tordo N., Poch O., Ermine A., Keith G., Rougeon F. Completion of the rabies virus genome sequence determination: highly conserved domains among the L (polymerase) proteins of unsegmented negative-strand RNA viruses. Virology. 1988 Aug;165(2):565–576. doi: 10.1016/0042-6822(88)90600-9. [DOI] [PubMed] [Google Scholar]
  33. Wiktor T. J., György E., Schlumberger D., Sokol F., Koprowski H. Antigenic properties of rabies virus components. J Immunol. 1973 Jan;110(1):269–276. [PubMed] [Google Scholar]
  34. Wunner W. H., Dietzschold B., Curtis P. J., Wiktor T. J. Rabies subunit vaccines. J Gen Virol. 1983 Aug;64(Pt 8):1649–1656. doi: 10.1099/0022-1317-64-8-1649. [DOI] [PubMed] [Google Scholar]
  35. Yewdell J. W., Bennink J. R., Smith G. L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785–1789. doi: 10.1073/pnas.82.6.1785. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES